Optimizing Therapy for Patients Radioactive Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC) : Episode 5
The Role of Molecular Diagnostics in Real-World DTC Management
Daniel Bowles, MD, explores the role of molecular testing in driving treatment decisions and its application in the initial diagnosis stage, while also discussing driver mutations, primary surgeries, and the importance of high-quality DNA and RNA, highlighting the 2-year window for durable RNA sequencing.
EP: 1.Differentiated Thyroid Cancer: Examining Key Epidemiological Trends
EP: 2.Exploring Incidence and Histology of Differentiated Thyroid Cancer
EP: 3.Determining Prognosis for Patients with Differentiated Thyroid Cancer
EP: 4.Predisposition for Patients Developing DTC: Age and Gender
Now Viewing
EP: 5.The Role of Molecular Diagnostics in Real-World DTC Management
EP: 6.Employing Liquid Biopsies and ctDNA in DTC Diagnostic Strategies
EP: 7.The Importance of Thyroidectomy in DTC Patient Care
EP: 8.Post-Thyroidectomy Management: Thyroid Hormone Replacement and TSH Suppression
EP: 9.Identifying RAI-Refractory Disease: A Key Aspect of DTC Management
EP: 10.SELECT Trial & DECISION Trial Outcomes and Lessons Learned
EP: 11.Determining Which DTC Patients May Benefit from Systemic Therapy
EP: 12.Exploring Real-World Evidence Presented at ATA 2023
EP: 13.Understanding the Impact of COSMIC-311 and Sequencing in DTC
EP: 14.Toxicity Profiles for DTC Guidelines Therapies
EP: 15.Addressing Unmet Needs and Challenges in RAI-R-DTC Treatment
EP: 16.Neoadjuvant Approach in RAI-R-DTC
EP: 17.Phase 2 ATLEP Trial Results
EP: 18.Reflecting on Differentiated Thyroid Cancer: Final Insights
Related Videos
